Cambridge Investment Research Advisors, Inc. Neurocrine Biosciences Inc Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 1,482 shares of NBIX stock, worth $170,459. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,482Holding current value
$170,459% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
96.2MCall Options Held
380KPut Options Held
382K-
Black Rock Inc. New York, NY14.2MShares$1.63 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.16 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$563 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$347 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$292 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...